[This entry is marked for removal.]

Cytogen Corporation of Princeton, NJ is a product-driven, oncology-focused biopharmaceutical company. Cytogen markets several products through its in- house oncology sales force: ProstaScint® (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer); BrachySeed™ I-125 and BrachySeed™ Pd-103 (two uniquely designed, next generation radioactive seed implants for the treatment of localized prostate cancer), and NMP22® BladderChek™ (a highly accurate and convenient antibody-based point-of-care staging test for bladder cancer detection). Cytogen has also developed Quadramet®, a skeletal targeting therapeutic radiopharmaceutical for the relief of bone pain in prostate and other types of cancer. Cytogen's pipeline comprises product candidates at various stages of clinical development, including fully human monoclonal antibodies and cancer vaccines based on PSMA (prostate specific membrane antigen) technology, which was exclusively licensed from Memorial Sloan-Kettering Cancer Center.
A license and marketing agreement with AMAG Pharmaceuticals Inc' (formerly Advanced Magnetics), to market the functional molecular imaging agent Combidex®, was terminated in 2007.

(DANTE) A technique used to place a saturation band over e.g. the myocardium. This technique includes spatial modulation of magnetization complementary and delays alternating with nutations for tailored excitation, followed by the application of a cine or real-time imaging. Because the saturated magnetization pattern moves with the atoms of the tissue, the cardiac motion shows up as deformations in the grid pattern in the resulting imaging sequence.

(ESR) Electron spin resonance is a spectroscopic technique to identify paramagnetic substances. This magnetic resonance phenomenon investigates the nature of the bonding within molecules by identifying unpaired electrons, e.g. in free radicals and their interaction with their immediate surroundings. The Larmor frequency are much higher than corresponding NMR frequencies in the same static magnetic field.
Nuclei with an odd number of neutrons and/or protons, because of their spin, react like tiny magnets and can be lined up in an applied magnetic field. Energy applied by alternating radio frequency radiation is absorbed when its frequency coincides with that of precession of the electron magnets. The spectrum of radiation absorbed as the field changes gives information valuable in chemistry, biology, and medicine since over 50 years.

(TrueFISP) True fast imaging with steady state precession is a coherent technique that uses a fully balanced gradient waveform. The image contrast with TrueFISP is determined by T2*//T1 properties and mostly depending on TR. The speed and relative motion insensitivity of acquisition help to make the technique reliable, even in patients who have difficulty with holding their breath.
Recent advances in gradient hardware have led to a decreased minimum TR. This combined with improved field shimming capabilities and signal to noise ratio, has allowed TrueFISP imaging to become practical for whole-body applications. There's mostly T2* weighting. With the used ultrashort TR-times T1 weighting is almost impossible. One such application is cardiac cine MR with high myocardium-blood contrast. Spatial and temporal resolution can be substantially improved with this technique, but contrast on the basis of the ratio of T2* to T1 is not sufficiently high in soft tissues. By providing T1 contrast, TrueFISP could then document the enhancement effects of T1 shortening contrast agents. These properties are useful for the anatomical delineation of brain tumors and normal structures. With an increase in SNR ratio with minimum TR, TrueFISP could also depict the enhancement effect in myoma uteri. True FSIP is a technique that is well suited for cardiac MR imaging. The imaging time is shorter and the contrast between the blood and myocardium is higher than that of FLASH.

See Steady State Free Precession.

Short name: Fe-EHPG, central moiety: Fe2+
[Fe(EHPG)-] Iron(III) ethylenebis-(2-hydroxyphenylglycine) is a stable complex that has been tested in animals as a hepatobiliary contrast agent in MRI.

See also Hepatobiliary Contrast Agents, Hepatobiliary Chelates, and contrast agents.